What is the revenue and EPS growth rate for Innovative year over year?

What is Innovative's latest dividend and current dividend yield?

What were the key takeaways from Innovative’s earnings call?

What factors drove the changes in Innovative's revenue and profit?

Did Innovative beat or miss consensus estimates last quarter?

What does Innovative do and what are its main business segments?

What is Innovative's gross profit margin?

What is the market's earnings forecast for Innovative next quarter?

- **Cannabis Regulatory Breakthrough**: Schedule III rescheduling could eliminate 280E tax penalty, +$3.7M in Q4 recoveries. 
- **Portfolio Turnaround**: 900K sq ft re-leasing pipeline, 26% of rent in high-growth states. 
- **Life Science Diversification**: $150M IQHQ investment, 25% pre-leasing, 6M sq ft pipeline decline. 
- **Financial Strength**: $107M liquidity, 10x debt coverage, $40M preferred stock issuance at 9.5%. 
- **Tenant Recovery**: 4Front/PharmaCann re-leasing at $10-15/sq ft, $7M judgment collection.

**【Management Opening Remarks】**
- 2025 performance highlights: $200M cash flows from operations, $275M capital investments (including $150M in IQHQ), and $105M total liquidity. 
- Life science sector optimism: improving demand in Boston and San Francisco, 6M sq ft construction pipeline decline to lowest since 2019. 
- Cannabis regulatory progress: President Trump's Schedule III rescheduling EO, potential 280E tax relief, and hemp-derived THC product restrictions starting Nov 2026.

**【CEO Commentary】**
- Regulatory tailwinds: Schedule III rescheduling could improve tenant cash flows and credit profiles. 
- Portfolio turnaround: 900K sq ft re-leasing pipeline across 16 properties in Virginia, PA, FL (26% of base rent). 
- Legal successes: $7M judgment against Temescal Wellness, active receivership management for 4Front, PharmaCann, and Gold Flora. 

**【CFO Financial Commentary】**
- Q4 2025 results: $66.7M revenue, $53.3M AFFO ($1.88/share), +10% QoQ driven by $3.7M in Gold Flora recoveries. 
- Capital market strength: $40M preferred stock issuance (9.5% yield), $100M IQHQ credit facility (6.1% rate), and $2B unencumbered asset base. 
- Balance sheet resilience: 10x debt service coverage, 1.4x net debt/EBITDA, $107M liquidity. 

**【Q&A Highlights】**
- Tenant health: Stronger operators (Curaleaf, Trulieve) refinancing, 4Front/PharmaCann re-leasing at minimal capex ($10-15/sq ft). 
- Dividend coverage: Normalized AFFO growth from IQHQ interest ($12M/yr) and re-leasing, no immediate dividend risk. 
- Legal costs: $2M/yr average, potential savings from resolving tenant disputes. 
- Life science diversification: 25% IQHQ pre-leasing, targeting 37M sq ft pipeline reduction by 2026.

Innovative Industrial Properties, Inc. (IIPR) Q4 2025 Earnings Call Transcript

- **Strategic Diversification**: $105M IQHQ investment with 14%+ returns, supported by $100M low-cost credit facility.
- **Cannabis Recovery**: 20% ABR default reduction, Illinois property recovery, and federal rescheduling momentum for senior adoption growth.
- **Financial Strength**: Q3 revenue $64.7M, 11x debt coverage, and $80M liquidity for disciplined growth.
- **Dividend Outlook**: IQHQ accretion and re-leasing could add $0.26-$0.28 to AFFO, supporting dividend sustainability.

**【Management Opening Remarks】**
- **IQHQ Investment**: Committed $105 million initially (including $100M credit facility and $5M preferred stock), with $165 million additional capital to be deployed through Q2 2027. Secured a new $100M revolving credit facility at 6.1% interest, reflecting strong lender confidence.
- **Portfolio Diversification**: Transitioning from cannabis-focused to a dual-track strategy, leveraging life sciences growth while maintaining cannabis leadership.

**【CEO Commentary】**
- **Cannabis Portfolio Challenges**: Ongoing receiverships for 4Front Ventures and Gold Flora; expects resolution in 3-9 months. Regained Illinois property by year-end, with NY, OH, PA cases pending.
- **Rescheduling Momentum**: Federal commentary supports cannabis rescheduling to Schedule III, potentially unlocking $64B in healthcare savings and driving senior adoption (9% CAGR vs. 3% for adults).
- **Strategic Patience**: Maintaining disciplined capital allocation, prioritizing accretive investments.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Total revenue $64.7M (+3% QoQ), AFFO $48.3M ($1.71/share). Liquidity of $80M, low leverage (13% debt-to-assets), and 11x debt service coverage.
- **IQHQ Accretion**: 14% blended return on IQHQ investments, 800bps spread over new credit facility. Expected to be highly accretive to AFFO.
- **Debt Management**: Evaluating refinancing for $250M unsecured bonds maturing Q1 2026, targeting conservative capital structure.

**【Q&A Highlights】**
- **Dividend Bridge**: IQHQ deployment and re-leasing could add $0.26-$0.28 to AFFO by Q4 2026, supporting dividend sustainability.
- **Tenant Default Reduction**: ABR in default declined from 27% to 20% since Q4 2024, driven by property recoveries and improved tenant health.
- **Life Sciences Risk**: IQHQ structured with common equity risk, no IIPR balance sheet exposure. Focus on high-quality assets with 27%+ occupancy growth potential.
- **Rescheduling Impact**: Federal action could reduce black market share, enhance tenant credit, and enable IIPR's sale-leaseback model expansion.

Innovative Industrial Properties, Inc. (IIPR) Q3 2025 Earnings Call Transcript

- **$270M Life Science Expansion**: Invested in IQHQ for 14%+ yield, diversifying beyond cannabis into high-growth life science markets with 5M+ sq. ft. pipeline.
- **Cannabis Challenges**: Q2 revenue down 12% due to tenant defaults, but cannabis sales growth outpaces traditional consumer goods.
- **Financial Strength**: $2.6B unencumbered assets, 11% debt-to-assets ratio, and $19M share buybacks.
- **Strategic Flexibility**: IQHQ ROFO offers 5M+ sq. ft. accretive growth, while maintaining cannabis sector leadership.

**【Management Opening Remarks】**
- Announced a $270 million strategic investment in IQHQ, a leading private life science REIT, to diversify beyond cannabis. The investment includes a $100 million revolving credit facility and up to $170 million in preferred stock, expected to yield over 14%.
- Highlighted IQHQ's 5 million sq. ft. portfolio across key life science markets (Boston, South San Francisco, San Diego, UK) and its pipeline of development projects. The investment provides a right of first offer (ROFO) on future asset sales, offering potential for 5+ million sq. ft. of accretive growth.
- Emphasized the life science sector's improving fundamentals, with 2025 fundraising at its highest since 2021 and declining new supply, positioning IQHQ for long-term growth.

**【CEO (Paul Smithers) Commentary】**
- Cannabis portfolio challenges persist due to tenant defaults (e.g., 4Front, Gold Flora, PharmaCann), with legal actions underway to recover properties. TILT Holdings is making partial rent payments while restructuring its plant-touching business.
- Despite macroeconomic and regulatory headwinds, U.S. cannabis sales growth outpaces traditional consumer goods, with Maryland, New York, and Ohio showing double-digit increases. However, the illicit market remains a significant threat, with California seizing $500 million in illegal cannabis last quarter.
- Reiterated commitment to the cannabis sector, noting a 7% CAGR to $44 billion by 2029, but acknowledged the need to explore complementary growth opportunities.

**【CFO (David Smith) Financial Commentary】**
- Q2 2025 revenue: $62.9 million (-12% QoQ) due to tenant defaults, with AFFO of $48.4 million ($1.71 per share, -12% QoQ). 
- Strong balance sheet with $2.6 billion in unencumbered assets, $190 million liquidity, and low leverage (11% debt-to-gross assets). 
- Repurchased 367,000 shares ($19.8 million) and issued preferred stock to fund the IQHQ investment.

**【Q&A Highlights】**
- **IQHQ Investment Rationale**: 14%+ yield vs. 16% dividend yield reflects strategic diversification and accretive returns. Flexibility to fund preferred stock tranches over 18 months allows capital allocation based on market conditions.
- **Conflict Mitigation**: Special committee and Board approval ensured alignment with shareholder interests, with no conflicts of interest identified.
- **Cannabis vs. Life Science Focus**: Maintains cannabis leadership while exploring accretive opportunities, with IQHQ offering immediate cash flow and diversification.
- **Tenant Default Impact**: Ongoing legal actions aim to recover properties, with re-leasing efforts in Michigan and California showing progress.


Innovative Industrial Properties, Inc. (IIPR) Q2 2025 Earnings Call Transcript

- **Q1 Results**: Revenue $71.7M (-6.5% Q/Q), AFFO $55.3M (-13% Q/Q) due to tenant defaults. 
- **Tenant Defaults**: 4 tenants in default; 205k sq ft Michigan facility re-leased in 3 weeks. 
- **Regulatory Progress**: STATES 2.0 Act introduced; PA, FL, MN advancing adult-use cannabis. 
- **Capital Actions**: $20M stock buybacks, $9M debt retired, $10M preferred stock issued. 
- **Balance Sheet**: $2.6B assets (85% unencumbered), debt/EBITDA 0.9x. 
- **Risks**: $5.8M security deposits exhausted, $4.5M cash collections from defaults. 


**【Management Opening Remarks】**
- Q1 2025 total revenue: $71.7 million (6.5% Q/Q decline due to tenant defaults). 
- AFFO: $55.3 million ($1.94 per share, 13% Q/Q decline). 
- Liquidity: $220 million (includes $20M stock buybacks and $9M debt retirement). 
- Strategic initiatives: 
  - Acquired 22k sq ft Maryland facility, sold Michigan property for $9M. 
  - Executed 211k sq ft new leases (e.g., 205k sq ft to Berry Green in Michigan). 
  - Issued default notices to 4 tenants, pursuing legal remedies. 

**【CEO Commentary】**
- Tenant defaults: 
  - Gold Flora (CA) in receivership; Tilt Holdings (partial payments). 
  - PharmaCann and 4Front Ventures: eviction proceedings underway. 
- Re-leasing progress: 
  - 205k sq ft Michigan facility re-leased to Berry Green in 3 weeks. 
  - 160k sq ft Pittsburgh facility leased to new operator. 
- Regulatory updates: 
  - STATES 2.0 Act introduced (federal cannabis legalization). 
  - DEA rescheduling of cannabis under consideration. 
  - PA, FL, MN advancing adult-use cannabis legalization. 
- Market outlook: U.S. cannabis sales projected to grow 7% YoY to $33.5B in 2025. 

**【CFO Financial Commentary】**
- GAAP net loss: $10.2 million (vs. $12.1M loss Q4 2024). 
- Non-GAAP metrics: 
  - EBITDA: $102.3 million (11% Q/Q decline). 
  - Debt/EBITDA: 0.9x (well below 3.0x target). 
- Capital actions: 
  - Repurchased $8.8M of 5.25% bonds at 85% of par. 
  - Issued $10.1M Series A preferred stock. 
  - $20M stock buyback program executed at $54.09/share. 
- Balance sheet strength: 
  - $2.6B gross assets, 85% unencumbered. 
  - Debt service coverage: 17x. 

**【Q&A Highlights】**
- Tenant default resolution: 
  - $5.8M security deposits applied to Q1 rent. 
  - $4.5M cash collections from defaulted tenants. 
- Re-leasing strategy: 
  - Focus on "best-in-class" operators with strong financials. 
  - 1M+ sq ft pipeline of re-leasable space. 
- Regulatory compliance: 
  - Uses third-party MSAs to maintain non-plant-touching status. 
- Liquidity deployment: 
  - $220M available for selective acquisitions. 
  - Evaluating accretive cannabis-related opportunities. 


Innovative Industrial Properties, Inc. (IIPR) Q1 2025 Earnings Call Transcript

- **Record Cash Flow**: Returned $210 million to shareholders in 2024, maintaining a 11% debt-to-gross assets ratio.
- **Swift Tenant Resolution**: PharmaCann's rent resumption and capital infusion highlight effective risk management.
- **Industry Growth**: 10% U.S. sales growth projected for 2025, driven by state expansions and reduced illicit market competition.
- **Liquidity Strength**: $235 million in available capital for strategic investments in a selective market.

**【CEO & Executive Chairman Summary】**
- **Revenue and Cash Flow**: Generated $308.5 million in total revenue and $255 million in cash flow from operations in 2024, returning $210 million to shareholders through dividends.
- **Investment Activity**: Deployed $70 million in capital to acquire two properties and enhance facility capacity, with $235 million in available liquidity for future strategic investments.
- **Tenant Leasing**: Executed new leases covering 530,000 square feet (6% of portfolio), achieving 98% occupancy across the operating portfolio.
- **PharmaCann Resolution**: Reached a swift resolution with PharmaCann, resuming rent payments on 9 of 11 leases and securing a capital infusion from their investors.

**【CFO Financial Highlights】**
- **Revenue Performance**: Year-over-year revenue decreased by less than 1% due to lease amendments and tenant partial payments, offset by rent escalations and new property acquisitions.
- **AFFO Metrics**: AFFO per share was $2.22 for the quarter, reflecting reduced rent collections but maintaining strong balance sheet metrics (11% debt-to-gross assets, 17x debt service coverage).
- **Liquidity**: Expanded revolving credit facility to $87.5 million and maintained over $235 million in total liquidity, supporting capital deployment flexibility.

**【Q&A Key Takeaways】**
- **Tenant Risk Management**: Emphasized strict enforcement of lease terms, with PharmaCann's resolution serving as a precedent for future tenant renegotiations.
- **Industry Growth Drivers**: Projected 10% U.S. cannabis sales growth in 2025, driven by state expansions (e.g., Pennsylvania, Florida) and reduced illicit market share.
- **Federal Policy Outlook**: Cautiously optimistic on DEA rescheduling efforts, with potential progress tied to White House policy directives.
- **Investment Strategy**: Focused on cultivation assets and multistate operators, with disciplined capital allocation to mitigate risk in a challenging market.

Innovative Industrial Properties, Inc. (IIPR) Q4 2024 Earnings Call Transcript

Innovative Industrial Properties (IIPR)-7 Nov 24-2024 Q3 Earnings call transcript

Innovative Industrial Properties (IIPR)-6 Aug 24-2024 Q2 Earnings call transcript

Innovative Industrial Properties (IIPR)-9 May 24-2024 Q1 Earnings call transcript

- **Revenue & AFFO Growth**: 12% revenue ($310M) and 10% AFFO ($256M) in 2023, with Q4 AFFO up 8% YoY to $64M.
- **Dividend Strength**: $7.22 annual dividend (80% payout ratio), up $0.02Q/Q to $1.82 per share.
- **Balance Sheet Excellence**: 12% debt-to-assets, 16x coverage, and $175M liquidity post-$45M credit facility expansion.
- **Strategic Leasing**: 600,000 sqft leased/LOI in 2023, including PharmaCann's NY expansion and Parallel's PA property re-leasing.
- **Regulatory Catalyst**: Potential 280e repeal could save MSOs $700M annually, with DEA reviewing HHS's Schedule III recommendation.

**【Management Opening Remarks】**
- Alan Gold highlighted 2023 performance: 12% revenue growth to $310 million, 10% AFFO growth to $256 million, and $7.22 in dividends declared. The company also expanded its credit facility to $45 million and reduced investment activity amid macroeconomic challenges.

**【CEO Commentary】**
- Paul Smithers emphasized the cannabis industry's 12% growth in 2023 and projected 10% growth in 2024. He noted indoor cultivation's premium over outdoor and the impact of illicit competition, particularly in New York. The potential rescheduling of cannabis to Schedule III could remove 280e taxes, benefiting operators.

**【CFO Financial Commentary】**
- David Smith reported Q4 2023 revenue of $79 million (12% YoY growth), net income of $41 million, and AFFO of $64 million (8% YoY growth). The company maintained a 12% debt-to-assets ratio and 16x debt service coverage. The $45 million credit facility and $9.6 million ATM issuance supported liquidity.

**【Q&A Highlights】**
- **Market Consolidation**: Paul Smithers noted weaker operators exiting mature markets, with 2023 seeing a 30-50% decline in MSO CapEx. However, indoor growers like IIP's tenants remain resilient.
- **Tenant Efficiency**: Ben Regin highlighted 600,000 sqft of leased/LOI space in 2023, driven by demand for indoor facilities. PharmaCann's New York expansion exemplifies tenant growth amid price compression.
- **Federal Tax Reform**: Alan Gold emphasized the potential $700 million annual tax savings for MSOs if 280e is repealed, citing DEA's ongoing review of HHS's Schedule III recommendation.
- **Investment Strategy**: Ben Regin stated 2024 will mirror 2023 with cautious, accretive investments, including $16 million for PharmaCann's NY expansion and $1.7 million collected from Parallel.
- **Rent Collection**: Catherine Hastings reported 100% Q4 collection, with 98% full-year coverage. Deferred rent programs for tenants like 4Front Illinois were restructured to align with revenue generation.


Actual										0.72	0.73	0.86	0.91	1.05	1.17	1.2	1.14	1.32	1.42	1.32	1.46	1.43	1.44	1.45	1.45	1.36	1.44	1.37	1.36	1.03	0.86	0.97	1.06
Forecast										0.7275	0.7525	0.785	1.042	0.972	1.114	1.162	1.245	1.358	1.364	1.304	1.24	1.3075	1.3433	1.4175	1.4075	1.4325	1.46	1.4467	1.36	1.145	0.9133	0.9033	1.0467
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.03%	-2.99%	+9.55%	-12.67%	+8.02%	+5.03%	+3.27%	-8.43%	-2.80%	+4.11%	+1.23%	+17.74%	+9.37%	+7.20%	+2.29%	+3.02%	-5.06%	-1.37%	-5.30%	0.00%	-10.04%	-5.84%	+7.38%	+1.27%

IIPR

IIPR fundamentals

IIPR Q4 2025 Earnings

Earnings Call

You can ask Aime

IIPR

IIPR fundamentals

IIPR Q4 2025 Earnings

Earnings Call

IIPR Earnings Call Summary for Q4/202512:00 PM on Feb 24, 2026

IIPR Earnings Call Summary for Q3/202512:00 PM on Nov 4, 2025

IIPR Earnings Call Summary for Q2/202512:00 PM on Aug 7, 2025

IIPR Earnings Call Summary for Q1/202512:00 PM on May 8, 2025

IIPR Earnings Call Summary for Q4/202412:00 PM on Feb 20, 2025

You can ask Aime